N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
High-risk Neuroblastoma|Neuroblastoma|Childhood Neuroblastoma
BIOLOGICAL: DANYELZA|BIOLOGICAL: Sargramostim|DRUG: Cytoxan|DRUG: Topotecan|DRUG: Vincristine|DRUG: Doxorubicin|DRUG: Ifosfamide|DRUG: Etoposide|DRUG: Carboplatin|DRUG: Irinotecan|DRUG: Temozolomide
Evaluate participant response, To assess the early Complete Response/CR rate in newly-diagnosed HR-NB patients., After 2 cycles of mAb-based therapy (each cycle is 21 days)
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.